Mesoblast Ltd Files March 2025 6-K Report

Ticker: MEOBF · Form: 6-K · Filed: Mar 7, 2025 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateMar 7, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: reporting, regulatory-filing

TL;DR

MESO files March 6-K, standard reporting update.

AI Summary

On March 6, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month of March 2025, indicating the company's ongoing reporting obligations. Mesoblast Limited is incorporated in Australia and its CEO is Silviu Itescu.

Why It Matters

This filing serves as an update on Mesoblast Limited's regulatory activities and disclosures for the month of March 2025, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine filing that does not appear to contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K filing is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of March 2025.

When was the announcement filed with the Australian Securities Exchange?

The announcement was filed on March 6, 2025.

Who is the Chief Executive Officer of Mesoblast Limited?

Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.

Where is Mesoblast Limited incorporated?

Mesoblast Limited is incorporated in Australia.

What is the SIC code for Mesoblast Limited?

The Standard Industrial Classification (SIC) code for Mesoblast Limited is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 7, 2025 by Silviu Itescu regarding MESOBLAST LTD (MEOBF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing